SCI Abstract

search
+
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule netw...
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
This phase 1 first-in-human study evaluated the safety, tolerability, and pharmacokinetics of MK-1088, a novel, small-mole...
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
Background: Relugolix has been used to treat advanced prostate cancer. This study assessed adverse events (AEs) associated...
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The...
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Obstacles facing chemotherapeutic drugs for cancers led scientists to load Gemcitabine (GEM) into nanocarriers like liposo...
Broad-spectrum anti-cancer activity of fused human arginase variants
Broad-spectrum anti-cancer activity of fused human arginase variants
The rapid increase in cancer cases worldwide necessitates the development of novel therapeutic approaches. Therapies targe...
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer....
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Sitravatinib (MGCD516) is an oral inhibitor of several closely related oncogenic tyrosine kinase receptors that include VE...
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
Although immune checkpoint inhibitors (ICI) are used for unresectable hepatocellular carcinoma (HCC), it is unclear whethe...
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor. This phase II trial evaluated the efficacy of ESK98...
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergisti...
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
Despite available treatments for acute lymphoblastic leukemia (ALL), the disease’s high clinical variability necessi...
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfun...
Effect of PAWI-2 on pancreatic cancer stem cell tumors
Effect of PAWI-2 on pancreatic cancer stem cell tumors
Worldwide, pancreatic cancer (PC) is a major health problem and almost 0.5 million people were diagnosed with PC ...
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer
The oral multikinase inhibitors sorafenib and lenvatinib are currently available as first-line treatment for patients with...
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
Pembrolizumab plus epacadostat (indoleamine 2,3-dioxygenase-1 inhibitor) was well tolerated in Japanese patients with adva...
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
Breast cancer is a leading cause of death in women worldwide. Cancer therapy based on stem cells is considered as a novel ...
Evolving or immutable - phase I solid tumor trials in the era of precision oncology
Evolving or immutable - phase I solid tumor trials in the era of precision oncology
In the era of precision oncology (PO), systemic therapies for patients (pts) with solid tumors have shifted from chemother...
In vitro results with minimal blood toxicity of a combretastatin A4 analogue
In vitro results with minimal blood toxicity of a combretastatin A4 analogue
Cancer is a disease caused by uncontrolled cell growth that is responsible for several deaths worldwide. Breast cancer is ...
Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients
Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients
The aim of the present study was to determine whether the trough plasma concentrations (C0) of regorafenib and its metabol...
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
Sutetinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and showed favorable efficacy and safety...
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
Platinum-based doublet chemotherapy is commonly used in the treatment of non-small cell lung cancer (NSCLC). A growing bod...
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small ...
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
MET exon 14 skipping alterations and MET amplifications are recognized as oncogenic and targetable genetic changes in canc...
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
MEK inhibitors have immunomodulatory activity and potential for synergistic activity when combined with PD-1 inhibitors. W...
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia
Blinatumomab is efficacious in patients with B-cell acute lymphoblastic leukemia (B-ALL), yet limited real-world data exis...
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
Immune checkpoint inhibitors are the leading approaches in tumor immunotherapy. The aim of the study was to establish reco...
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas
Myristoylation, the N-terminal addition of the fatty acid myristate to proteins, regulates membrane-bound signal transduct...
177Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model
177Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model
In the current in-vivo study we demonstrate the potential of the radiolabeled nanoparticle 177Lu-SN201 as an effective ant...
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ram...
Load More
format_indent_increase